Capital World Investors holds 5.6% of Oruka
Capital World Investors, a division of Capital Research and Management Company and its investment management affiliates, reports beneficial ownership of Oruka Therapeutics, Inc. common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Capital World Investors, a division of Capital Research and Management Company and its investment management affiliates, reports beneficial ownership of Oruka Therapeutics, Inc. common stock. The group is deemed to beneficially own 3,401,639 shares, representing 5.6% of Oruka’s 60,312,101 shares believed to be outstanding.
Capital World Investors holds sole voting power and sole dispositive power over all 3,401,639 shares, with no shared voting or dispositive power reported. The filing is signed by Timothy J. Moon, Vice President and Senior Counsel of Capital Research and Management Company.
Key Figures
Key Terms
Schedule 13G regulatory
beneficial owner financial
sole voting power financial
dispositive power financial
percent of class financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of Oruka Therapeutics (ORKA) does Capital World Investors report owning?
AI-generated analysis. How Rhea-AI works. Not financial advice.